Posted March 13, 2008
Salix Acquires Rights to Family of Drugs from European Firm
Post a comment
Print this storyE-mail story
Share
Raleigh, N.C. —
Salix Pharmaceuticals (NYSE: SLXP) has acquired a group of drugs from European pharmaceutical firm Dr Falk Pharma for an upfront fee, milestone payments and royalties.
Specific financial terms were not disclosed.
Salix is focused on development and sale of gastrointestinal drugs.
The Dr Falk drugs are already licensed for sale in Europe but have not been approved for use in the United States. The products are sold in the U.K. for treatment of ulcerative colitis, Crohn’s disease and chronic diarrhea due to colitis.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
